{"id":746054,"date":"2019-04-22T05:45:00","date_gmt":"2019-04-22T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/"},"modified":"2025-05-12T08:58:11","modified_gmt":"2025-05-12T12:58:11","slug":"fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/","title":{"rendered":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)"},"content":{"rendered":"<p class=\"bwalignc\">       Approval Based on Results of KEYNOTE-426, Where KEYTRUDA in        Combination With Axitinib Reduced the Risk of Death by Nearly Half        Compared to Sunitinib     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta<br \/>\n      (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of<br \/>\n      patients with advanced renal cell carcinoma (RCC). The approval is based<br \/>\n      on findings from the pivotal Phase 3 KEYNOTE-426 trial, which<br \/>\n      demonstrated significant improvements in overall survival (OS),<br \/>\n      progression-free survival (PFS) and objective response rate (ORR) for<br \/>\n      KEYTRUDA in combination with axitinib (KEYTRUDA-axitinib combination)<br \/>\n      compared to sunitinib. Consistent results were observed across<br \/>\n      pre-specified subgroups, IMDC risk categories and PD-L1 tumor expression<br \/>\n      status. For the main efficacy outcome measures of OS and PFS, the<br \/>\n      KEYTRUDA-axitinib combination reduced the risk of death by 47% compared<br \/>\n      to sunitinib (HR=0.53 [95% CI, 0.38-0.74]; p&lt;0.0001); for PFS, the<br \/>\n      KEYTRUDA-axitinib combination showed a reduction in the risk of<br \/>\n      progression of disease or death of 31% compared to sunitinib (HR=0.69<br \/>\n      [95% CI, 0.57-0.84]; p=0.0001). The ORR, an additional efficacy outcome<br \/>\n      measure, was 59% for patients who received the KEYTRUDA-axitinib<br \/>\n      combination (95% CI, 54-64) and 36% for those who received sunitinib<br \/>\n      (95% CI, 31-40) (p&lt;0.0001). This is the first indication for KEYTRUDA in<br \/>\n      advanced RCC, the most common type of kidney cancer, and the first<br \/>\n      anti-PD-1 therapy FDA-approved as part of a combination regimen that<br \/>\n      significantly improved OS, PFS, and ORR versus sunitinib in patients<br \/>\n      with advanced RCC.\n    <\/p>\n<p>\n      \u201cThis represents a new treatment option for patients with advanced renal<br \/>\n      cell carcinoma, who will now have access to KEYTRUDA as part of a<br \/>\n      first-line combination regimen,\u201d said Dr. Scot Ebbinghaus, vice<br \/>\n      president, clinical research, Merck Research Laboratories. \u201cToday\u2019s<br \/>\n      approval reflects Merck\u2019s commitment to patients with cancer and further<br \/>\n      supports the use of KEYTRUDA to help improve survival outcomes for<br \/>\n      patients with advanced renal cell carcinoma.\u201d\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur with KEYTRUDA, including pneumonitis, colitis, hepatitis,<br \/>\n      endocrinopathies, nephritis and renal dysfunction, severe skin<br \/>\n      reactions, solid organ transplant rejection, and complications of<br \/>\n      allogeneic hematopoietic stem cell transplantation (HSCT). Based on the<br \/>\n      severity of the adverse reaction, KEYTRUDA should be withheld or<br \/>\n      discontinued and corticosteroids administered if appropriate. KEYTRUDA<br \/>\n      can also cause severe or life-threatening infusion-related reactions.<br \/>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. For more information, see \u201cSelected<br \/>\n      Important Safety Information\u201d below.\n    <\/p>\n<p>\n      \u201cGiven the aggressive nature of the disease, many patients with advanced<br \/>\n      renal cell carcinoma need additional treatment options that can help<br \/>\n      improve survival outcomes,\u201d said Dr. Brian Rini, medical oncologist at<br \/>\n      Cleveland Clinic Cancer Center and professor of medicine at the<br \/>\n      Cleveland Clinic Lerner College of Medicine of Case Western Reserve<br \/>\n      University. \u201cPembrolizumab in combination with axitinib offers an<br \/>\n      important new therapeutic option for physicians to consider when<br \/>\n      approaching initial treatment for patients newly diagnosed with advanced<br \/>\n      renal cell carcinoma.\u201d Dr. Rini reports consulting and research funding<br \/>\n      from Merck.\n    <\/p>\n<p>\n      <b>About KEYNOTE-426<\/b>\n    <\/p>\n<p>\n      The approval was based on data from the pre-specified interim analysis<br \/>\n      of the Phase 3 KEYNOTE-426 trial, a randomized, multi-center, open-label<br \/>\n      trial conducted in 861 patients who had not received systemic therapy<br \/>\n      for advanced RCC. Patients were enrolled regardless of PD-L1 tumor<br \/>\n      expression status. Randomization was stratified by International<br \/>\n      Metastatic RCC Database Consortium (IMDC) risk categories (favorable<br \/>\n      versus intermediate versus poor) and geographic region (North America<br \/>\n      versus Western Europe versus \u201cRest of the World\u201d). Patients with active<br \/>\n      autoimmune disease requiring systemic immunosuppression within the last<br \/>\n      two years were ineligible.\n    <\/p>\n<p>\n      Patients were randomized (1:1) to one of the following treatment arms:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        KEYTRUDA 200 mg intravenously every three weeks up to 24 months in<br \/>\n        combination with axitinib 5 mg orally, twice daily (n=432).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Sunitinib 50 mg orally, once daily for four weeks and then off<br \/>\n        treatment for two weeks (n=429).\n      <\/li>\n<\/ul>\n<p>\n      Among the 861 patients, the study population characteristics were:<br \/>\n      median age of 62 years (range, 26 to 90); 38% age 65 or older; 73% male;<br \/>\n      79% White and 16% Asian; 19% and 80% of patients had a baseline<br \/>\n      Karnofsky Performance Status (KPS) of 70 to 80 and 90 to 100,<br \/>\n      respectively; and patient distribution by IMDC risk categories was 31%<br \/>\n      favorable, 56% intermediate, and 13% poor.\n    <\/p>\n<p>\n      Treatment with the KEYTRUDA-axitinib combination continued until RECIST<br \/>\n      v1.1 (modified to follow a maximum of 10 target lesions and a maximum of<br \/>\n      5 target lesions per organ)-defined progression of disease or<br \/>\n      unacceptable toxicity. The main efficacy outcome measures were OS and<br \/>\n      PFS as assessed by BICR according to modified RECIST v1.1. Additional<br \/>\n      efficacy outcome measures included ORR, as assessed by BICR.\n    <\/p>\n<p>\n      The trial demonstrated statistically significant improvements in OS,<br \/>\n      PFS, and ORR in patients randomized to receive the KEYTRUDA-axitinib<br \/>\n      combination compared to sunitinib.\n    <\/p>\n<p>\n      With a median follow-up time of 12.8 months (range, 0.1 to 22 months),<br \/>\n      OS was significantly improved in patients who received the<br \/>\n      KEYTRUDA-axitinib combination compared to sunitinib (HR=0.53 [95% CI,<br \/>\n      0.38-0.74]; p&lt;0.0001). Estimated 12-month OS rates were 90% (95% CI,<br \/>\n      86-92) with the KEYTRUDA-axitinib combination versus 78% (95% CI, 74-82)<br \/>\n      with sunitinib. Median OS was not reached with either treatment<br \/>\n      regimen.&nbsp;Progression-free survival was also significantly improved with<br \/>\n      the KEYTRUDA-axitinib combination compared to sunitinib (HR=0.69 [95%<br \/>\n      CI, 0.57-0.84]; p=0.0001). Median PFS was 15.1 months (95% CI,<br \/>\n      12.6-17.7) in patients receiving the KEYTRUDA-axitinib combination<br \/>\n      versus 11.1 months (95% CI, 8.7-12.5) with sunitinib. In the study, the<br \/>\n      ORR was 59% for patients who received the KEYTRUDA-axitinib combination<br \/>\n      (95% CI, 54-64) and 36% for those who received sunitinib (95% CI, 31-40)<br \/>\n      (p&lt;0.0001), with a complete response rate of 6% and 2% and a partial<br \/>\n      response rate of 53% and 34%, for patients receiving the<br \/>\n      KEYTRUDA-axitinib combination versus sunitinib, respectively.\n    <\/p>\n<p>\n      In KEYNOTE-426, the safety of KEYTRUDA in combination with axitinib was<br \/>\n      investigated in patients with previously untreated, advanced RCC. The<br \/>\n      median duration of exposure to the combination therapy of KEYTRUDA and<br \/>\n      axitinib was 10.4 months (range, 1 day to 21.2 months). Fatal adverse<br \/>\n      reactions occurred in 3.3% of patients receiving KEYTRUDA in combination<br \/>\n      with axitinib. Serious adverse reactions occurred in 40% of patients<br \/>\n      receiving KEYTRUDA in combination with axitinib. Serious adverse<br \/>\n      reactions in \u22651% of patients receiving KEYTRUDA in combination with<br \/>\n      axitinib included hepatotoxicity (7%), diarrhea (4.2%), acute kidney<br \/>\n      injury (2.3%), dehydration (1%), and pneumonitis (1%). Permanent<br \/>\n      discontinuation due to an adverse reaction of either KEYTRUDA or<br \/>\n      axitinib occurred in 31% of patients; 13% KEYTRUDA only, 13% axitinib<br \/>\n      only, and 8% both drugs. The most common adverse reaction (&gt;1%)<br \/>\n      resulting in permanent discontinuation of KEYTRUDA, axitinib or the<br \/>\n      combination was hepatotoxicity (13%), diarrhea\/colitis (1.9%), acute<br \/>\n      kidney injury (1.6%), and cerebrovascular accident (1.2%). The most<br \/>\n      common adverse reactions (\u226520%) in patients receiving in patients<br \/>\n      receiving KEYTRUDA and axitinib were diarrhea (56%), fatigue\/asthenia<br \/>\n      (52%), hypertension (48%), hepatotoxicity (39%), hypothyroidism (35%),<br \/>\n      decreased appetite (30%), palmar-plantar erythrodysesthesia (28%),<br \/>\n      nausea (28%), stomatitis\/mucosal inflammation (27%), dysphonia (25%),<br \/>\n      rash (25%), cough (21%), and constipation (21%).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 950 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma. The recommended dose of KEYTRUDA in patients with<br \/>\n      unresectable or metastatic melanoma is 200 mg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the adjuvant treatment of patients with<br \/>\n      melanoma with involvement of lymph node(s) following complete resection.<br \/>\n      The recommended dose of KEYTRUDA for the adjuvant treatment of adult<br \/>\n      patients with melanoma is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease recurrence, unacceptable<br \/>\n      toxicity, or for up to 12 months in patients without disease recurrence.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with carboplatin and either paclitaxel or<br \/>\n      paclitaxel protein-bound, is indicated for the first-line treatment of<br \/>\n      patients with metastatic squamous NSCLC.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with stage III NSCLC who are not candidates for surgical<br \/>\n      resection or definitive chemoradiation, or metastatic NSCLC, and whose<br \/>\n      tumors express PD-L1 [tumor proportion score (TPS) \u22651%] as determined by<br \/>\n      an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In NSCLC, the recommended dose of KEYTRUDA is 200 mg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for the chemotherapy agents<br \/>\n      administered in combination with KEYTRUDA, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA 200 mg<br \/>\n      is administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks until disease progression, unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after 3 or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA 200 mg is administered<br \/>\n      as an intravenous infusion over 30 minutes every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression. In pediatric patients with cHL,<br \/>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes at a<br \/>\n      dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA 200 mg is administered as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with PMBCL, KEYTRUDA is administered<br \/>\n      as an intravenous infusion over 30 minutes at a dose of 2 mg\/kg (up to a<br \/>\n      maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [combined positive score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA 200 mg<br \/>\n      is administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA 200 mg is administered as<br \/>\n      an intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression. In pediatric patients with MSI-H cancer,<br \/>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes at a<br \/>\n      dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS \u22651) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after two or<br \/>\n      more prior lines of therapy including fluoropyrimidine- and<br \/>\n      platinum-containing chemotherapy and if appropriate, HER2\/neu-targeted<br \/>\n      therapy. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and durability of response. Continued approval for<br \/>\n      this indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is 200 mg as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Hepatocellular Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n      carcinoma (HCC) who have been previously treated with sorafenib. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Merkel Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with recurrent locally advanced or metastatic Merkel cell carcinoma.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA in adults is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. The recommended dose of KEYTRUDA in pediatric patients is 2<br \/>\n      mg\/kg (up to a maximum of 200 mg), administered as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Renal Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with axitinib, is indicated for the first-line<br \/>\n      treatment of patients with advanced renal cell carcinoma. In renal cell<br \/>\n      carcinoma, KEYTRUDA 200 mg is administered as an intravenous infusion<br \/>\n      over 30 minutes every 3 weeks in combination with 5 mg axitinib orally<br \/>\n      twice daily until disease progression, unacceptable toxicity, or for<br \/>\n      KEYTRUDA, up to 24 months in patients without disease progression. When<br \/>\n      axitinib is used in combination with KEYTRUDA, dose escalation of<br \/>\n      axitinib above the initial 5 mg dose may be considered at intervals of<br \/>\n      six weeks or longer. See also the Prescribing Information for<br \/>\n      recommended axitinib dosing information.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients with various cancers<br \/>\n      receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4<br \/>\n      (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65\/790) of NSCLC<br \/>\n      patients receiving KEYTRUDA as a single agent, including Grades 3-4 in<br \/>\n      3.2% of patients, and occurred more frequently in patients with a<br \/>\n      history of prior thoracic radiation (17%) compared to those without<br \/>\n      (7.7%).\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis, or Hepatoxicity (in Combination With<br \/>\n      Axitinib)<\/b>\n    <\/p>\n<p>\n      <i>Immune-Mediated Hepatitis<\/i>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <i>Hepatotoxicity (in Combination With Axitinib)<\/i>\n    <\/p>\n<p>\n      KEYTRUDA in combination with axitinib can cause hepatic toxicity with<br \/>\n      higher than expected frequencies of Grades 3 and 4 ALT and AST<br \/>\n      elevations compared to KEYTRUDA alone. Grades 3 and 4 increased ALT and<br \/>\n      AST were seen in 20% and 13% of patients, respectively. Monitor liver<br \/>\n      enzymes before initiation of and periodically throughout treatment.<br \/>\n      Consider more frequent monitoring of liver enzymes as compared to when<br \/>\n      the drugs are used in monotherapy. For elevated liver enzymes, interrupt<br \/>\n      KEYTRUDA and axitinib, and consider administering corticosteroids as<br \/>\n      needed.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC, occurring in 15% (28\/192) of patients. Hyperthyroidism occurred<br \/>\n      in 3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%),<br \/>\n      and thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade<br \/>\n      2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials, including cHL, and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      (9%) developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients With Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In trials in patients with multiple myeloma, the addition of KEYTRUDA to<br \/>\n      a thalidomide analogue plus dexamethasone resulted in increased<br \/>\n      mortality. Treatment of these patients with a PD-1 or PD-L1 blocking<br \/>\n      antibody in this combination is not recommended outside of controlled<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. Advise women of this potential risk.<br \/>\n      In females of reproductive potential, verify pregnancy status prior to<br \/>\n      initiating KEYTRUDA and advise them to use effective contraception<br \/>\n      during treatment and for 4 months after the last dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse<br \/>\n      reactions in 14% of 509 patients; the most common (\u22651%) were pneumonitis<br \/>\n      (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions<br \/>\n      occurred in 25% of patients receiving KEYTRUDA. The most common adverse<br \/>\n      reaction (\u226520%) with KEYTRUDA was diarrhea (28%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and<br \/>\n      either paclitaxel or paclitaxel protein-bound in metastatic squamous<br \/>\n      NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were febrile neutropenia, pneumonia, and urinary<br \/>\n      tract infection. Adverse reactions observed in KEYNOTE-407 were similar<br \/>\n      to those observed in KEYNOTE-189 with the exception that increased<br \/>\n      incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs<br \/>\n      25%) were observed in the KEYTRUDA and chemotherapy arm compared to the<br \/>\n      placebo and chemotherapy arm in KEYNOTE-407.\n    <\/p>\n<p>\n      In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      19% of 636 patients; the most common were pneumonitis (3%), death due to<br \/>\n      unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious<br \/>\n      adverse reactions reported in at least 2% of patients were pneumonia<br \/>\n      (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural<br \/>\n      effusion (2.2%). The most common adverse reaction (\u226520%) was fatigue<br \/>\n      (25%).\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC; the most common<br \/>\n      was pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC who<br \/>\n      received KEYTRUDA as a monotherapy, with the exception of increased<br \/>\n      incidences of facial edema and new or worsening hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with gastric cancer were similar<br \/>\n      to those occurring in patients with melanoma or NSCLC who received<br \/>\n      KEYTRUDA as a monotherapy.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with HCC were generally similar<br \/>\n      to those in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy, with the exception of increased incidences of ascites (8%<br \/>\n      Grades&nbsp;3-4) and immune-mediated hepatitis (2.9%). Laboratory<br \/>\n      abnormalities (Grades&nbsp;3-4) that occurred at a higher incidence were<br \/>\n      elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).\n    <\/p>\n<p>\n      Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse<br \/>\n      reactions occurring in patients with MCC were generally similar to those<br \/>\n      occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a<br \/>\n      higher incidence were elevated AST (11%) and hyperglycemia (19%).\n    <\/p>\n<p>\n      In KEYNOTE-426, when KEYTRUDA was administered in combination with<br \/>\n      axitinib, fatal adverse reactions occurred in 3.3% of 429 patients.<br \/>\n      Serious adverse reactions occurred in 40% of patients, the most frequent<br \/>\n      of which (\u22651%) included hepatotoxicity (7%), diarrhea (4.2%), acute<br \/>\n      kidney injury (2.3%), dehydration (1%), and pneumonitis (1%). Permanent<br \/>\n      discontinuation due to an adverse reaction occurred in 31% of patients;<br \/>\n      KEYTRUDA only (13%), axitinib only (13%), and the combination (8%). The<br \/>\n      most common adverse reactions (&gt;1%) resulting in permanent<br \/>\n      discontinuation of KEYTRUDA, axitinib or the combination were<br \/>\n      hepatotoxicity (13%), diarrhea\/colitis (1.9%), acute kidney injury<br \/>\n      (1.6%), and cerebrovascular accident (1.2%). When KEYTRUDA was used in<br \/>\n      combination with axitinib, the most common adverse reactions (\u226520%) were<br \/>\n      diarrhea (56%), fatigue\/asthenia (52%), hypertension (48%),<br \/>\n      hepatotoxicity (39%), hypothyroidism (35%), decreased appetite (30%),<br \/>\n      palmar-plantar erythrodysesthesia (28%), nausea (28%),<br \/>\n      stomatitis\/mucosal inflammation (27%), dysphonia (25%), rash (25%),<br \/>\n      cough (21%), and constipation (21%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      Because of the potential for serious adverse reactions in breastfed<br \/>\n      children, advise women not to breastfeed during treatment and for 4<br \/>\n      months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a trial, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with various cancers,<br \/>\n      including unapproved usages, were administered KEYTRUDA 2 mg\/kg every 3<br \/>\n      weeks. Patients received KEYTRUDA for a median of 3 doses (range 1\u201317<br \/>\n      doses), with 34 patients (85%) receiving 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults;<br \/>\n      adverse reactions that occurred at a higher rate (\u226515% difference) in<br \/>\n      these patients when compared to adults under 65 years of age were<br \/>\n      fatigue (45%), vomiting (38%), abdominal pain (28%), increased<br \/>\n      transaminases (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About the Merck Access Program for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      At Merck, we are committed to supporting accessibility to our cancer<br \/>\n      medicines. Merck provides multiple programs to help ensure that<br \/>\n      appropriate patients who are prescribed KEYTRUDA have access to our<br \/>\n      anti-PD-1 therapy. The Merck Access Program provides reimbursement<br \/>\n      support for patients receiving KEYTRUDA, including information to help<br \/>\n      with out-of-pocket costs and co-pay assistance for eligible patients.<br \/>\n      Merck also offers free product through our patient assistance program to<br \/>\n      eligible patients, primarily the uninsured, who, without our assistance,<br \/>\n      could not afford their medicine. More information is available by<br \/>\n      calling 855-257-3932 or visiting&nbsp;<a href=\"https:\/\/www.merckaccessprogram-keytruda.com\/\" rel=\"nofollow\">www.merckaccessprogram-keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck\u2019s Patient Support Program for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Merck is committed to helping provide patients and their caregivers<br \/>\n      support throughout their treatment with KEYTRUDA. The KEY+YOU Patient<br \/>\n      Support Program provides a range of resources and services. For further<br \/>\n      information and to sign up, patients and physicians may call 85-KEYTRUDA<br \/>\n      (855-398-7832) or visit&nbsp;<a href=\"https:\/\/www.keytruda.com\/\" rel=\"nofollow\">www.keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site <span class=\"bwuline\">(<\/span><br \/>\n<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\"><br \/>\n<span class=\"bwuline\">www.sec.gov<\/span><br \/>\n<\/a><br \/>\n<span class=\"bwuline\">)<\/span>.\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Investor:<br \/>Teri Loxam<br \/>(908) 740-1986     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the pivotal Phase 3 KEYNOTE-426 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for KEYTRUDA in combination with axitinib (KEYTRUDA-axitinib combination) compared to sunitinib. Consistent results were observed across pre-specified subgroups, IMDC risk categories and PD-L1 tumor expression status. For the main efficacy outcome measures of OS and PFS, the KEYTRUDA-axitinib combination reduced the risk of death by 47% compared to sunitinib (HR=0.53 [95% CI, 0.38-0.74]; p&lt;0.0001); for PFS, the KEYTRUDA-axitinib combination<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289,56],"class_list":["post-746054","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the pivotal Phase 3 KEYNOTE-426 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for KEYTRUDA in combination with axitinib (KEYTRUDA-axitinib combination) compared to sunitinib. Consistent results were observed across pre-specified subgroups, IMDC risk categories and PD-L1 tumor expression status. For the main efficacy outcome measures of OS and PFS, the KEYTRUDA-axitinib combination reduced the risk of death by 47% compared to sunitinib (HR=0.53 [95% CI, 0.38-0.74]; p&lt;0.0001); for PFS, the KEYTRUDA-axitinib combination\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"29 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/\",\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-04-22T05:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the pivotal Phase 3 KEYNOTE-426 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for KEYTRUDA in combination with axitinib (KEYTRUDA-axitinib combination) compared to sunitinib. Consistent results were observed across pre-specified subgroups, IMDC risk categories and PD-L1 tumor expression status. For the main efficacy outcome measures of OS and PFS, the KEYTRUDA-axitinib combination reduced the risk of death by 47% compared to sunitinib (HR=0.53 [95% CI, 0.38-0.74]; p&lt;0.0001); for PFS, the KEYTRUDA-axitinib combination","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:11+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"29 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/","name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-04-22T05:45:00+00:00","dateModified":"2025-05-12T12:58:11+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Inlyta\u00ae (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e6b333a2-1bfd-4dba-ab89-041fa239b08b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-in-Combination-With-Inlyta-axitinib-as-First-Line-Treatment-for-Patients-With-Advanced-Ren-BG9TH.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746054\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746054"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}